BOLDER BIOTECHNOLOGY INC
PEG IL-11 and multi-protein drug combinations for treating hematopoietic acute radiation syndrome (H-ARS)
- Sector
- Biotech
- Headquarters
- Boulder, CO
- Total capital
- $9.3M
- Federal grants
- $6.2M
- 11 awards · 2015–2024
- Rank in peer group#513 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $3.1M
- 1 award · Health and Human S
- Rank in Biotech#107 of 4373
- Granted patents
- 6
- 13 pending · first 2016
- Rank in peer group#58 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation$717K
- Federal grantHealth and Human S · Phase I · Improving survival from Burkholderia pseudomallei and other pathogenic intracellular bacteria$296K
- Federal contractHealth and Human S · Advanced Development Of BBT-059 As A Radiation Medical Countermeasure For Dosing Up To 48H Post Exposure"$3.1M
- Federal grantHealth and Human S · Phase II · Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation$1M
- Federal grantHealth and Human S · Phase II · Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation$1M
- Federal grantDefense · Phase I · Evaluating BBT-059 as a medical countermeasure to protect against hematopoietic acute radiation syndrome$250K
- Federal grantHealth and Human S · Phase I · Stimulating innate immunity to protect against Ebola virus infection$300K
Show 5 earlier federal awards
- Federal grantHealth and Human S · Phase I · Stimulating innate immunity to protect against Ebola virus infection$300K
- Federal grantHealth and Human S · Phase I · Novel drugs combinations for improving survival from Acute Radiation Syndrome when administered 48h postirradiation$294K
- Federal grantHealth and Human S · Phase I · Novel drugs combinations for improving survival from Acute Radiation Syndrome when administered 48h postirradiation$594K
- Federal grantHealth and Human S · Phase I · Novel drugs combinations for improving survival from Acute Radiation Syndrome when administered 48h postirradiation$300K
- Federal grantHealth and Human S · Phase II · Long-Acting G-CSF Analog for Treating ARS$1.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#58 · top 11%
- Linked publications#44 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 6 granted of 19- PendingMethods And Compositions For Enhancement Of Tumor Immunogenicity And Stimulating Anti-tumor Immune Responses In An AnimalUSPTOApplication 18726712
- PendingMethods and Compositions for Enhancement of Stem Cell-based Immunomodulation and Tissue RepairUSPTOApplication 17390190
- PendingLong Acting Proteins And Peptides And Methods Of Making And Using The SameUSPTOApplication 16664474
Show all 19 patent records
- Methods And Compositions For Enhancement Of Tumor Immunogenicity And Stimulating Anti-tumor Immune Responses In An AnimalFeb 27, 2025 · Application 18726712Pending
- Methods and Compositions for Enhancement of Stem Cell-based Immunomodulation and Tissue RepairFeb 3, 2022 · Application 17390190Pending
- Long Acting Proteins And Peptides And Methods Of Making And Using The SameSep 10, 2020 · Application 16664474Pending
- Methods And Use Of Growth Hormone Supergene Family Protein Analogs For Treatment Of Radiation ExposureMay 19, 2020 · US 10,653,752Granted
- Cysteine Analogs Of EXENDIN-4Dec 17, 2019 · US 10,508,131Granted
- Cysteine Variants Of INTERLEUKIN-11 And Methods Of Use ThereofSep 5, 2019 · Application 16408748Pending
- A Method To Increase The Number Of Circulating Platelets By Administering Pegylated Cysteine Variants Of IL-11Jun 25, 2019 · US 10,329,337Granted
- Methods And Use Of Growth Hormone Supergene Family Protein Analogs For Treatment Of Radiation ExposureJul 10, 2018 · US 10,016,485Granted
- Methods For Making Proteins Containing Free Cysteine ResiduesDec 21, 2017 · Application 15414020Pending
- Methods Of Preparing Cysteine Variants Of Human Recombinant IL-11May 2, 2017 · US 9,637,530Granted
- Long Acting Proteins And Peptides And Methods Of Making And Using The SameJan 19, 2017 · Application 15049246Pending
- Methods For Making Proteins Containing Free Cysteine ResiduesAug 25, 2016 · Application 14598094Pending
- NH2-TERMINAL Glutamine Modified Cysteine Variants Of Interferon GammaMar 29, 2016 · US 9,296,804Granted
- Derivatives Of Growth Hormone And Related ProteinsJun 12, 2014 · Application 14089498Pending
- Enzyme Conjugates For Use As Detoxifying AgentsApplication PCTUS2005044273Pending
- Methods and compositions for enhancement of tumor immunogenicity and stimulating anti-tumor immune responses in an animalApplication 63297157Pending
- Long Acting Proteins And Peptides And Methods Of Making And Using The SameApplication PCTUS2007087657Pending
- Long Acting Vegf Inhibitors And Methods Of UseApplication PCTUS2006038727Pending
- Methods and Compositions for Enhancement of Stem Cell-based Immunomodulation and Tissue RepairApplication 63058743Pending
Recent research by its founders
- Data from: Longitudinal serum proteomic profiling of nonhuman primates exposed to total-body gamma-radiation and treated with BBT-05920260 cites
- Longitudinal Serum Proteomic Profiling of Nonhuman Primates Exposed to Total-body Gamma Radiation and Treated with BBT-05920260 cites
- Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-05920260 cites
Related companies, and why
- NOVOMEDIX LLCSimilar federal contract value in Biotech · $3.3M in contracts
- SynthegoSimilar federal contract value in Biotech · $3.2M in contracts
- NEOVAXSYN INCSimilar federal contract value in Biotech · $3.2M in contracts
- BIOMATRICA, INC.Similar federal contract value in Biotech · $3M in contracts
- APOGEE BIOTECHNOLOGY CORPORATIONSimilar federal contract value in Biotech · $3M in contracts
- AKINA, INC.Similar federal contract value in Biotech · $3M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .